{
    "clinical_study": {
        "@rank": "30062", 
        "arm_group": {
            "arm_group_label": "Lift thread", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The objective of this clinical test is to verify the safety and efficacy of MINTLIFT\u00ae, used\n      for the purpose of improving the appearance of the nasolabial fold on both sides of the\n      face."
        }, 
        "brief_title": "Evaluate the Efficacy and Safety of MINTLIFT\u00ae Group for Nasolabial Fold", 
        "condition": "Nasolabial Fold", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Individuals who desire an improvement in the appearance of the nasolabial fold on\n             both sides of the face and who have a score of 3 or 4 on the Wrinkle Severity Rating\n             Scale (WSRS) at the time of the screening and at the baseline time point\n\n          -  Individuals who have consented to abstain from any other dermatological procedures or\n             treatments, including treatments for wrinkle reduction in the facial area, during the\n             duration of this clinical test\n\n        Exclusion Criteria:\n\n          -  Subjects who have a scar or hypertrophic scar or a history of keloid conditions that\n             may affect the determination of effect\n\n          -  Subjects allergic to local anesthetics or sleep anesthetics\n\n          -  Subjects whose ALT/AST ratio is 2.5 times or more greater than the normal upper limit\n\n          -  Subjects who have been administered an anticoagulant (with the exception of low\n             dosage aspirin (100mg, up to 300mg/day)) within 2 weeks of the date of the screening,\n             or who require an anticoagulant during the period of the clinical test\n\n          -  Subjects who have been administered systemic corticosteroids or anabolic steroids\n             within two weeks of the date of the screening or who require their administration\n             during the period of the clinical test (note, however, that the administration of\n             inhaled corticosteroids in a standardized dosage is permissible)\n\n          -  Subjects who have been administered Vitamin E or non-steroidal anti-inflammatory\n             drugs within 1 week of the date of the screening\n\n          -  Subjects who have used Topical liniments in the facial area (steroids, retinoids:\n             only medical drugs are included in this criteria, with the exclusion of cosmetic\n             products) within 4 weeks of the date of the screening or who plan on continuing usage\n             during the period of the clinical test\n\n          -  Subjects who have received wrinkle reduction treatment using CaHA within 1 year of\n             the date of the screening\n\n          -  Subjects who have received wrinkle reduction treatment using collagen or HA filler\n             within 6 months of the date of the screening, or who have received acne treatment,\n             skin regeneration procedures, or cosmetic surgical procedures (including Botox\n             injections) in the facial area\n\n          -  Subjects who have a permanent skin expanding implant such as Softform or silicon\n             inserted in the facial area\n\n          -  Subjects who have scars in the facial area requiring treatment that has not healed\n             for a period of 1 year or longer, or who have a scar or trace in the area on which\n             the clinical test device will applied.\n\n          -  Subjects who have a chronic or recurrent infection or a history of inflammatory\n             disease that may affect this clinical test\n\n          -  Subjects who have experienced severe allergies such as symptoms of anaphylaxis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "62", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01848717", 
            "org_study_id": "HANS_MINTLIFT_1101"
        }, 
        "intervention": {
            "arm_group_label": "Lift thread", 
            "intervention_name": "MINTLIFT\u00ae", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 3, 2013", 
        "location": {
            "contact": {
                "email": "tonhuk28@naver.com", 
                "last_name": "MIN", 
                "phone": "+82-2-6299-1525"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Chung-Ang University Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single\u2010Center, Single Arm, Pre-post Test Design, Open Clinical Study to Evaluate the Efficacy and Safety of MINTLIFT\u00ae Group for Nasolabial Fold", 
        "overall_contact": {
            "email": "beomjoon74@gmail.com", 
            "last_name": "Beom Joon KIM, MD, PhD", 
            "phone": "+82-2-6299-1525"
        }, 
        "overall_official": {
            "affiliation": "Department of Dermatology", 
            "last_name": "Beom Joon KIM, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The percentage of the subjects within the test group who demonstrated wrinkle improvement to -1 or below in WSRS in the 12th week following the application of the device in comparison to the condition prior to the application (12th week- prior to application) as determined by an independent evaluator", 
            "measure": "The percentage of the subjects who demonstrated wrinkle improvement to -1 or below in WSRS as determined by an independent evaluator", 
            "safety_issue": "No", 
            "time_frame": "12th week of the application of the test device"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01848717"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chung-Ang University Hospital", 
            "investigator_full_name": "Beom Joon Kim", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "The percentage of the subjects who demonstrated wrinkle improvement to -1 or below in WSRS as determined by an independent evaluator", 
                "safety_issue": "No", 
                "time_frame": "in the 4th, 8th and 24th week following the application of the device"
            }, 
            {
                "measure": "The percentage of the subjects who demonstrated wrinkle improvement to -1 or below in WSRS as determined by the investigator", 
                "safety_issue": "No", 
                "time_frame": "in the 4th, 8th, 12th and 24th week following the application of the device"
            }, 
            {
                "measure": "The average of the differences between the baseline and the WSRS evaluated by the independent evaluator", 
                "safety_issue": "No", 
                "time_frame": "in the 4th, 8th, 12th and 24th week following the application of the test device"
            }, 
            {
                "measure": "The average of the differences between the baseline and the WSRS evaluated by the subject", 
                "safety_issue": "No", 
                "time_frame": "in the 4th, 8th, 12th and 24th week following the application of the test device"
            }, 
            {
                "measure": "The average value of Global Aesthetic Improvement Scale (GAIS) scores as determined by the investigator and the distribution of scores", 
                "safety_issue": "No", 
                "time_frame": "in the 12th and 24th week following the application of the test device"
            }, 
            {
                "measure": "The average value of GAIS scores as determined by the subject and the distribution of scores", 
                "safety_issue": "No", 
                "time_frame": "in the 12th and 24th week following the application of the test device"
            }
        ], 
        "source": "Chung-Ang University Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "HansBiomed Co.,Ltd.", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Chung-Ang University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}